Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for EBV Prevention in Kidney Transplant
NCT04989491Phase 4Recruiting
- Sponsor
- Strasbourg University Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in Epstein-Barr virus infection, Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by Strasbourg University Hospital. Started Dec 2021; status: recruiting.
02
Drugs
rituximab
03
Conditions
Epstein-Barr virus infectionPost-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT04989491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989491.